Exelixis | EXEL - Net Income


Exelixis reported $210.47M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY -3.25B 20.43B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Genmab DKK 31M 370M Dec/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR -801M 3.6B Dec/2025
Takeda JPY -24.32B 127.96B Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026